Navigation Links
Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
Date:5/13/2008

g the next fiscal year for

treatment of acute congestive heart failure;

-- Advancing new Palatin compound PL-6983, which in animal models causes

significantly lower increases in blood pressure than seen with

bremelanotide, into Phase 1 clinical studies for treatment of male and

female sexual dysfunction;

-- Continuing its melanocortin receptor-based collaboration with

AstraZeneca AB on developing compounds for treating obesity; and

-- Effecting an immediate reduction in force of 30% of the Company's

employees.

"Palatin has had a strong and productive research effort focused on two challenging and exciting scientific areas: melanocortin and natriuretic peptide receptors. We have generated a substantial amount of data and an extensive product portfolio that allows us numerous exciting opportunities to drive value for our shareholders," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. Dr. Spana continued, "Concentrating our efforts on value drivers and matching our resources to those projects with the highest potential for near-term success is our immediate priority."

The Company believes that the staff reduction aligns the Company's human resources with its new strategic objectives and will allow the Company to effectively advance its development and clinical programs. The downsizing is expected to result in annual savings of approximately $3 million. Palatin will record an estimated $400,000 charge for severance and related costs in the quarter ending June 30, 2008. The Company, which ended the March 31, 2008 quarter with $17.6 million of cash, cash equivalents and available-for-sale investments, anticipates that the restructuring will reduce its cash burn rate to approximately $16 million over the next four quarters.

Financial Results

Palatin reported a net loss of $5.1 million, or $(0.06) per basic and diluted share, for the quarter ende
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
2. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
3. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
4. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
7. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Veran Medical Technologies Secures $4.75M in First Institutional Funding
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. InSet Technologies Appoints Jon Tremmel to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... September 2, 2015 BiondVax Pharmaceuticals Ltd. ... National Institute of Allergy and Infectious Diseases (NIAID), part of ... of Health and Human Services (HHS), to launch a new ... United States in the 2015-16 timeframe. The trial ... Multimeric-001 (M-001), as a primer vaccine, which would be administered ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to creating professional commercial video content, to analysis of athletic performance. Producing ... that go by too quickly to process with the naked eye. , ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
... EXTON, Pa., Feb. 5 ViroPharma Incorporated,(Nasdaq: ... financial officer,and chief operating officer of ViroPharma, will ... 12:30 P.M. ET on Monday, February 11, 2008. ... New York., ViroPharma,s presentation will be webcast ...
... Feb. 5 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... meeting between Kiwa CEO and Board Chairman, ... the Department of Biology, the University of ... in research and,development (R&D) of plant growth ...
... Covance Inc. (NYSE:,CVD) today announced that it will ... Device Conference on February 6th,at 9:20 am ET. Investors ... http://www.covance.com . In order to register and download any ... with headquarters in Princeton, New Jersey, is one of ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 2Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 3
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
(Date:8/10/2015)... The latest 364 page report from business intelligence ... border security market . Visiongain assesses that ... Now: Border security is hard to achieve and harder ... issue you need to know about - and more importantly, ... how this will impact your company and the border security ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... Chemical communication within insect species is often much more ... such as ladybird beetles, they release an alarm pheromone, ... aphids to walk around or drop from the plant. ... Letters, researchers at the University and Max-Planck-Institute in Jena, ...
... to survive, it must elude the ever vigilant immune sentinels ... if it resides in nondividing cells and doesn’t produce any ... cells. If the virus targets one of the many cell ... some viruses, like the gamma-herpesvirus, infect B cells of the ...
... gene they suspect plays an important role in triggering ... century-and-a-half ago. , And the pathogen that contains this ... the modern world?on the order of billions of dollars ... Avr3a, in a study that appears online in the ...
Cached Biology News:How A Latent Virus Eludes Immune Defenses 2How A Latent Virus Eludes Immune Defenses 3Researchers find gene that may be at root of potato blight 2Researchers find gene that may be at root of potato blight 3
ID clarifier: With ethidium bromide (50 μg/ml)...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
... RNA Sample Buffer is ... buffer for experimental samples and ... sample buffer needs no dilution ... and denaturing gels. Simply mix ...
... Mouse RAW 264. 7 cells were cultured in ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: